Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th ...

Piper Sandler analyst maintains an Overweight rating on Teva, citing positive feedback on duvakitug's potential in treating ...

BUSINESS OPERATING PROFIT FORECAST: Business operating profit--one of the company's preferred metrics, which strips out exceptional items--is forecast at 2.08 billion euros, according to the Vara ...

Keith Ellison said he's reached a deal with Danish pharmaceutical company Novo Nordisk to keep the cost of insulin at $35 a ...

21 January 2025 UK trade association weighs in on Microsoft UPC appeal which deals with issue of representation | Former CIPA head says court should not “divide” European patent profession | SMEs ...

Atalanta Therapeutics, a biotechnology company pioneering RNA interference (RNAi) for the treatment of neurological diseases, today announced the completion of a $97 million Series B financing to ...

The bulk annuity transaction for the scheme has fully secured the benefits of 4,900 retirees and 5,600 deferred members. The ...

Legal & General Assurance Society Limited (“Legal & General”) has completed a £1.4 billion buy-in with the Sanofi Pension Scheme (“the Scheme”), securing the benefits of 4,900 retirees and 5,600 ...

Atalanta Therapeutics has bagged $97 million, money the biotech plans to use to launch clinical trials for its small ...

Atalanta Therapeutics is building on the growing attention around RNAi-based medicines with its $97 million Series B financing and plans to enter the clinic.

Legal & General closes £1.4bn bulk annuity buy-in with Sanofi Pension Scheme To access the premium content on InsuranceERM, ...

Sanofi Pension Scheme has completed a £1.4bn (€1.7bn) buy-in securing the benefits of 4,900 retirees and 5,600 deferred ...